At the 2018 British Oncology Pharmacy Association (BOPA) Annual Symposium, Simon Cheesman, MRPharmS, of University College London, London, UK, presented the experiences at University College Hospital London of making the switch to biosimilar rituximab for the treatment of selected patients receiving treatment for follicular lymphoma. One year on, we are joined by Mr Cheesman at the 2018 BOPA Annual Symposium in Birmingham, UK, to hear how this switch has impacted patients responses and treatment costs over the past 12 months.
Content on www.vjoncology.com and www.vjhemonc.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
The switch to biosimilar rituximab at UCH: 12 months on
